FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W122986880> ?p ?o ?g. }

• W122986880 endingPage "339" @default.
• W122986880 startingPage "333" @default.
• W122986880 abstract "PURPOSE Buruli ulcer is a human skin disease caused by Mycobacterium ulcerans infection, which is characterized by massive skin ulceration and persistent necrotic change. In recent years Buruli ulcer has rapidly emerged as an increasingly important cause of human morbidity around the world. The disease is endemic at least 32 countries in Africa, Western Pacific, Asia and South America, and it is considered the third most common mycobacterial infection of humans after tuberculosis and leprosy. An effective chemotherapeutic regimen against Buruli ulcer disease has not been established to date. In this study, the inhibitory effect of rifalazil (RLZ) against M. ulcerans was assessed in experimentally infected mice and compared to that of rifampicin (RFP). MATERIALS AND METHODS Five-week-old BALB/c female mice were challenged with 25 microliters (CFU = 4 x 10(4) of M. ulcerans cultured in Middlebrook 7H9 broth in bilateral hind footpads. Mice were administered per os with a suspension of RLZ or RFP at 2.5, 5, or 10 mg/kg once daily 5 times per week starting from one day up to 6 weeks after infection. During the treatment, mice were observed weekly for footpad skin lesions and examined for footpad swelling. In addition, CFU enumeration was done on both hind footpads and spleen at 2, 4, and 6 weeks after initiating treatment. RESULTS In the infected control mice group, slightly erythematous lesions and moderate swelling of footpads were observed 4 weeks after the infection. Ulcerative lesion was observed 6 weeks after the infection. Mean log10 CFU/footpad (FP) was 5.22 on day 1 after the infection and increased to 5.56, 6.29, and 7.33 at 2, 4, and 6 weeks after treatment was initiated in the treated groups. On the other hand, no visible erythema, swelling or ulcerative lesion in footpads were observed in RLZ-administered groups. Furthermore, log10 CFU/FP decreased to 4.14 after only 2 weeks of initiating treatment in 2.5 mg/kg administered group, i.e. the lowest dose employed group. Log10 CFU/FP decreased to < 2.1 in 6 weeks in the 10 mg/kg administered group, which was close to the detection limit (< 1.7) of the CFU assay. By contrast, inhibitory effect on disease progression and reduction of CFU were observed only in the group of mice given 10 mg/kg among RFP-administered groups: the reduction of CFU was not observed in the early period but 6 weeks after initiating treatment. CONCLUSION These results clearly demonstrate that the in vivo anti-M.ulcerans activity of RLZ is much higher than RFP. RLZ activity against M. ulcerans can be expected to control the disease progression in the clinical applications." @default.
• W122986880 created "2016-06-24" @default.
• W122986880 creator A5064254227 @default.
• W122986880 creator A5069900158 @default.
• W122986880 creator A5070886551 @default.
• W122986880 creator A5089729737 @default.
• W122986880 date "2004-05-15" @default.
• W122986880 modified "2023-09-24" @default.
• W122986880 title "Comparison of inhibitory effect of rifalazil and rifampicin against Mycobacterium ulcerans infection induced in mice" @default.
• W122986880 cites W1496093212 @default.
• W122986880 cites W1540229307 @default.
• W122986880 cites W1958329876 @default.
• W122986880 cites W1978966442 @default.
• W122986880 cites W1997313637 @default.
• W122986880 cites W2034423023 @default.
• W122986880 cites W2042926720 @default.
• W122986880 cites W2069909891 @default.
• W122986880 cites W2077408214 @default.
• W122986880 cites W2083684746 @default.
• W122986880 cites W2087148207 @default.
• W122986880 cites W2096606546 @default.
• W122986880 cites W2102015592 @default.
• W122986880 cites W2109637803 @default.
• W122986880 cites W2115565208 @default.
• W122986880 cites W2120992076 @default.
• W122986880 cites W2124307580 @default.
• W122986880 cites W2125687656 @default.
• W122986880 cites W2130744004 @default.
• W122986880 cites W2134484307 @default.
• W122986880 cites W2137250263 @default.
• W122986880 cites W2137478946 @default.
• W122986880 cites W2332760268 @default.
• W122986880 cites W2335208177 @default.
• W122986880 cites W2462243302 @default.
• W122986880 doi "https://doi.org/10.11400/kekkaku1923.79.333" @default.
• W122986880 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15211873" @default.
• W122986880 hasPublicationYear "2004" @default.
• W122986880 type Work @default.
• W122986880 sameAs 122986880 @default.
• W122986880 citedByCount "5" @default.
• W122986880 countsByYear W1229868802018 @default.
• W122986880 countsByYear W1229868802022 @default.
• W122986880 crossrefType "journal-article" @default.
• W122986880 hasAuthorship W122986880A5064254227 @default.
• W122986880 hasAuthorship W122986880A5069900158 @default.
• W122986880 hasAuthorship W122986880A5070886551 @default.
• W122986880 hasAuthorship W122986880A5089729737 @default.
• W122986880 hasConcept C142724271 @default.
• W122986880 hasConcept C203014093 @default.
• W122986880 hasConcept C2776261420 @default.
• W122986880 hasConcept C2778607973 @default.
• W122986880 hasConcept C2779134260 @default.
• W122986880 hasConcept C2780661791 @default.
• W122986880 hasConcept C2780695269 @default.
• W122986880 hasConcept C2780931953 @default.
• W122986880 hasConcept C2781069245 @default.
• W122986880 hasConcept C2781156865 @default.
• W122986880 hasConcept C71924100 @default.
• W122986880 hasConceptScore W122986880C142724271 @default.
• W122986880 hasConceptScore W122986880C203014093 @default.
• W122986880 hasConceptScore W122986880C2776261420 @default.
• W122986880 hasConceptScore W122986880C2778607973 @default.
• W122986880 hasConceptScore W122986880C2779134260 @default.
• W122986880 hasConceptScore W122986880C2780661791 @default.
• W122986880 hasConceptScore W122986880C2780695269 @default.
• W122986880 hasConceptScore W122986880C2780931953 @default.
• W122986880 hasConceptScore W122986880C2781069245 @default.
• W122986880 hasConceptScore W122986880C2781156865 @default.
• W122986880 hasConceptScore W122986880C71924100 @default.
• W122986880 hasIssue "5" @default.
• W122986880 hasLocation W1229868801 @default.
• W122986880 hasLocation W1229868802 @default.
• W122986880 hasOpenAccess W122986880 @default.
• W122986880 hasPrimaryLocation W1229868801 @default.
• W122986880 hasRelatedWork W1540229307 @default.
• W122986880 hasRelatedWork W1609116314 @default.
• W122986880 hasRelatedWork W1989152374 @default.
• W122986880 hasRelatedWork W2000099672 @default.
• W122986880 hasRelatedWork W2020493615 @default.
• W122986880 hasRelatedWork W2060887070 @default.
• W122986880 hasRelatedWork W2077408214 @default.
• W122986880 hasRelatedWork W2109637803 @default.
• W122986880 hasRelatedWork W2124307580 @default.
• W122986880 hasRelatedWork W2125687656 @default.
• W122986880 hasRelatedWork W2134325004 @default.
• W122986880 hasRelatedWork W2377641284 @default.
• W122986880 hasRelatedWork W2386603327 @default.
• W122986880 hasRelatedWork W2399075709 @default.
• W122986880 hasRelatedWork W2404142541 @default.
• W122986880 hasRelatedWork W2413397491 @default.
• W122986880 hasRelatedWork W256314307 @default.
• W122986880 hasRelatedWork W3005642992 @default.
• W122986880 hasRelatedWork W3011844850 @default.
• W122986880 hasRelatedWork W579087215 @default.
• W122986880 hasVolume "79" @default.
• W122986880 isParatext "false" @default.
• W122986880 isRetracted "false" @default.
• W122986880 magId "122986880" @default.

• next